| 2025-12-12 |
复牌提示：
2025-12-11 14:10:41 停牌，复牌日期 2025-12-11 14:20:41
|
| 2025-12-12 |
详情>>
股本变动：
变动后总股本102.34万股
变动原因 ▼▲
- 原因：
- The underwriter exercised the warrants to cause the company to issue 426,390 shares of common stock
|
| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-35.74美元,归母净利润-809.13万美元,同比去年增长-26.03%
|
| 2025-10-27 |
股东大会：
将于2025-12-11召开股东大会
会议内容 ▼▲
- 1.To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock, par value $0.01 per share (“Common Stock”), underlying certain warrants issued by us pursuant to those certain Inducement Letters, dated as of September 17, 2025, by and among us and certain holders named on the signatory page thereto (the “Inducement Letters”), and the Engagement Letter, by and between us and H.C. Wainwright & Co., LLC (the “Placement Agent”), dated as of December 8, 2024 (the “Engagement Letter”), in an amount equal to or in excess of 20% of our Common Stock outstanding immediately prior to the issuance of such warrants (the “Issuance Proposal”);
2.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board, effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, including stock held by the Company as treasury shares, at a ratio between 1-for-5 and 1-for-15 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement;
3.To approve an amendment to our Charter, in substantially the form attached to the proxy statement as Annex B, to, at the discretion of the Board, increase the authorized number of shares of our Common Stock from 100,000,000 to 5,000,000,000 shares (“Authorized Stock Increase Proposal”);
4.To approve an adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes to establish a quorum or in favor of the Issuance Proposal, Reverse Stock Split Proposal, and the Authorized Stock Increase Proposal (the “Adjournment Proposal”).
|
| 2025-10-23 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-2.15美元,归母净利润-470.41万美元,同比去年增长-8.48%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-1.22美元,归母净利润-218.5万美元,同比去年增长11.07%
|
| 2025-05-08 |
详情>>
内部人交易：
Tucker Joseph Edward等共交易3笔
|
| 2025-04-15 |
股东大会：
将于2025-05-29召开股东大会
会议内容 ▼▲
- 1.To elect six directors to serve until the Company’s 2026 annual meeting of stockholders or until their successors are duly elected and qualified (“Election of Directors”);
2.To approve by a non-binding advisory vote the compensation of the Company’s named executive officers, as disclosed in this proxy statement (the “Say-on-Pay Proposal”);
3.To authorize the Board of Directors of the Company (the “Board”) to amend the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board, effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.01 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-5 to 1-for-50 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement (the “Reverse Stock Split”); provided however that the Board shall be authorized to effect the Reverse Stock Split only if the Company receives a Delisting Determination (defined in the accompanying proxy statement) from The NASDAQ Stock Market LLC due to a default of the Minimum Bid Price Requirement (defined in the accompanying proxy statement) (the “Conditional Reverse Stock Split Proposal”);
4.To ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (the “Auditor Ratification Proposal”);
5.To approve a complete or partial adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the foregoing proposals or to establish a quorum (the “Adjournment Proposal”);
6.To transact such other business that is properly presented at the Annual Meeting.
|
| 2025-03-28 |
详情>>
业绩披露：
2024年年报每股收益-19.04美元,归母净利润-957.5万美元,同比去年增长45.16%
|
| 2025-01-29 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2024-12-18 |
股东大会：
将于2025-01-17召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.01 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio between 1-for-10 and 1-for-100 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement;
2.To approve an adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.95美元,归母净利润-642.03万美元,同比去年增长54.22%
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-0.75美元,归母净利润-433.63万美元,同比去年增长61.29%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.61美元,归母净利润-245.69万美元,同比去年增长48.82%
|
| 2024-04-16 |
股东大会：
将于2024-05-28召开股东大会
会议内容 ▼▲
- 1.To elect six directors to serve until the Company’s 2025 annual meeting of stockholders or until their successors are duly elected and qualified (“Election of Directors”);
2.To approve by a non-binding advisory vote the compensation of the Company’s named executive officers, as disclosed in this proxy statement (the “Say-on-Pay Proposal”);
3.To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (the “Auditor Ratification Proposal”);
4.To recommend, by a non-binding advisory vote, whether the non-binding advisory vote to approve the compensation of our named executive officers should occur every one year, every two years, or every three years (the “Say-on-Frequency Proposal”);
5.To transact such other business that is properly presented at the Annual Meeting and any adjournments, continuations or postponements thereof.
|
| 2024-03-26 |
详情>>
业绩披露：
2023年年报每股收益-8.09美元,归母净利润-1745.88万美元,同比去年增长7.14%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-6.62美元,归母净利润-1402.28万美元,同比去年增长-40.24%
|
| 2023-09-18 |
股东大会：
将于2023-11-02召开股东大会
会议内容 ▼▲
- 1.To elect five directors, to serve until the Company’s 2024 annual meeting of stockholders or until their successors are duly elected and qualified (“Election of Directors”);
2.To approve by a non-binding advisory vote the compensation of the Company’s named executive officers, as disclosed in this proxy statement (the “Say-on-Pay Proposal”);
3.To ratify the appointment of Marcum LLP (formerly Friedman LLP) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (the “Auditor Ratification Proposal”);
4.To approve proposed amendments to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended, in substantially the form attached to the proxy statement as Annex A (the “Incentive Plan Proposal”);
5.To approve the issuance of shares of common stock to Lincoln Park Capital Fund, LLC pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d) (the “Nasdaq Proposal”);
6.To transact such other business that is properly presented at the annual meeting and any adjournments, continuations or postponements thereof.
|
| 2023-08-11 |
详情>>
业绩披露：
2023年中报每股收益-5.35美元,归母净利润-1120.06万美元,同比去年增长-51.43%
|
| 2022-09-23 |
股东大会：
将于2022-10-28召开股东大会
会议内容 ▼▲
- 1.The election of seven directors, to serve until the Company’s 2023 annual meeting of stockholders or until their successors are duly elected and qualified (“Election of Directors”);
2.A non-binding advisory vote to approve the compensation of the Company’s named executive officers (the “Say-on-Pay Proposal”);
3.The ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (the “Auditor Ratification Proposal”).
|
| 2022-07-14 |
详情>>
拆分方案：
每50.0000合并分成1.0000股
|
| 2022-05-31 |
股东大会：
将于2022-07-14召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”), in substantially the form attached to the proxy statement as Annex A, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.01 per share (“Common Stock”), including stock held by the Company as treasury shares, at a ratio of 1-for-10 to 1-for-100 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement;
2.To approve an amendment to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Incentive Plan”), in substantially the form attached to the proxy statement as Annex B, to (i) increase the aggregate number of shares available for the grant of awards by 7,304,107 shares to a total of 10,000,000 shares, and (ii) add an “evergreen” provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of Common Stock to any person or entity, to the extent necessary so that the number of shares of our Common Stock authorized for issuance under the Incentive Plan will equal the greater of (x) 10,000,000 shares, and (y) 15% of the total number of shares of our Common Stock outstanding as of such issuance date (the “Incentive Plan Proposal”);
3.To approve an adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”).
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-13 |
股东大会：
将于2021-05-14召开股东大会
会议内容 ▼▲
- 1. To ratify the filing and effectiveness of the certificate of amendment to the Company’s amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware on December 30, 2020 (the “Reverse Stock Split Amendment”) and the one-for-four reverse stock split of the Company’s common stock (the “2020 Reverse Stock Split”) that was effected thereby and became effective on December 30, 2020 (collectively, the “Reverse Stock Split Amendment Ratification”);
2. To approve an adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the Reverse Stock Split Amendment Ratification (the “Adjournment Proposal”).
|
| 2020-12-31 |
详情>>
拆分方案：
每4.0000合并分成1.0000股
|
| 2020-11-13 |
股东大会：
将于2020-12-23召开股东大会
会议内容 ▼▲
- 1.The Ameri Share Issuance Proposal-to approve, for purposes of complying with Nasdaq Listing Rule 5635(a), the issuance of Ameri securities to Jay Pharma Inc., a Canada corporation (“Jay Pharma”), equity holders and to other parties in connection with the Offer, the Tender Agreement, dated as of August 12, 2020, as it may be amended, by and among Ameri, Jay Pharma, and the other signatories thereto, and the transactions contemplated thereby, including but not limited to the issuance of shares of common stock of Ameri in connection with the Offer (the “Resulting Issuer”) to Jay Pharma equity holders, warrants to purchase Resulting Issuer common stock to holders of certain outstanding warrants to purchase Jay Pharma common shares, Series B Warrants to purchase Resulting Issuer common stock to be issued to Alpha Capital Anstalt (“Alpha”), shares of Series B non-voting preferred stock, par value $0.01 per share, which are convertible into shares of Resulting Issuer common stock subject to a 9.99% beneficial ownership blocker (the “Series B Preferred Stock”) to be issued to Alpha and shares of Resulting Issuer common stock to a financial advisor of Jay Pharma and Ameri, as Offer consideration pursuant to the terms and conditions of the Tender Agreement (the “Ameri Share Issuance Proposal”);
2.The Ameri Future Share Issuance Proposal-to approve, for purposes of complying with Nasdaq Listing Rule 5635(a), the potential future issuance of shares of Resulting Issuer common stock pursuant to the anti-dilution terms of the Securities Purchase Agreement, dated as of January 10, 2020, by and between Alpha and Jay Pharma, and certain warrants to be issued to Alpha immediately prior to the completion of the Offer (the “Ameri Future Share Issuance Proposal”);
3.The Reverse Stock Split Proposal-to approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split with a ratio between 1-for-2 and 1-for-25 with respect to the issued and outstanding common stock of the Resulting Issuer immediately following the Offer (the “Reverse Stock Split Proposal”);
4.The Spin-Off Proposal-to approve that certain Share Purchase Agreement, dated January 10, 2020 (the “Share Purchase Agreement”), by and between Ameri and Ameri100 Inc. (“Private Ameri”) pursuant to which Ameri will contribute, transfer and convey to Private Ameri all of the issued and outstanding equity interests of the existing subsidiaries of Ameri, constituting the entire business and operations of Ameri and its subsidiaries (the “Spin-Off Proposal”);
5.The A&R Charter Proposal-to approve an amendment and restatement to our amended and restated certificate of incorporation (the “A&R Charter Proposal”);
6.The Incentive Plan Proposal-to approve the 2020 Employee, Director and Consultant Equity Incentive Plan (the “Incentive Plan Proposal”);
7.The Put Right Proposal-with respect to the warrants issued to Alpha on August 4, 2020 (the “Alpha Warrants”), to approve, in accordance with Nasdaq Listing Standard Rule 5635(d), a put right which would require Ameri to repurchase the unexercised portion of the Alpha Warrants for the sum of $0.60 per warrant share, payable in cash or shares of common stock, at our discretion (the “Put Right Proposal”);
8.The Bonus Shares Proposal-to approve the issuance by Ameri of an aggregate of 642,050 restricted shares of common stock to Ameri to officers, employees and consultants, as required by and in accordance with NASDAQ Listing Rule 5635 (the “Bonus Shares Proposal”);
9.The Conversion Proposal-to approve, for purposes of Nasdaq Rules 5635, the issuance of shares of common stock upon the exchange of promissory notes in one or more private placement transactions (the “Conversion Proposal”);
10.The Adjournment Proposal-to consider and vote upon a proposal to adjourn the special meeting to a later date or dates, if necessary, to permit the solicitation of additional proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve one or more proposals presented to stockholders for vote (the “Adjournment Proposal”).
|
| 2020-11-04 |
股东大会：
将于2020-12-15召开股东大会
会议内容 ▼▲
- 1.To elect four directors, to serve until the Company’s 2021 annual meeting of stockholders and until their successors are duly elected and qualified;
2.To ratify the appointment of our independent auditors;
3.To transact such other business as may properly come before the annual meeting or any adjournment(s), postponement(s) or other delay(s) thereof.
|
| 2019-11-25 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2019-09-27 |
股东大会：
将于2019-10-29召开股东大会
会议内容 ▼▲
- 1.To elect four directors, to serve until the Company’s 2019 annual meeting of stockholders and until their successors are duly elected and qualified;
2.To ratify the appointment of our independent auditors;
3.To authorize an amendment to our Certificate of Incorporation to effect a reverse stock split of our issued and outstanding common stock at a specific ratio, within a range of 1-for-5 and 1-for-25, to be determined by our Board of Directors in its sole discretion and effected, if at all, within one year of the date the proposal is approved by stockholders (the “Reverse Stock Split Proposal”);
4.To transact such other business as may properly come before the annual meeting or any adjournment(s), postponement(s) or other delay(s) thereof.
|
| 2018-08-22 |
股东大会：
将于2018-09-27召开股东大会
会议内容 ▼▲
- 1.To approve for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance by the Company of shares of common stock pursuant to the terms of the private placement financing transaction (“Private Placement”) contemplated by two substantively similar Securities Purchase Agreements, one dated July 25, 2018 and one dated August 21, 2018 (the “Securities Purchase Agreements”), by and among the Company and certain institutional and/or accredited investors, and the other documents and agreements related thereto, including shares that are issuable upon exercise of warrants issued in connection with the Private Placement, without giving effect to the caps on issuing shares contained therein (the “Nasdaq 20% Issuance Proposal”);
2.To transact such other business that may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2018-07-16 |
股东大会：
将于2018-08-16召开股东大会
会议内容 ▼▲
- 1.To elect five directors, to serve until the Company’s 2019 annual meeting of stockholders and until their successors are duly elected and qualified;
2.To ratify the appointment of our independent auditors;
3.To conduct an advisory (non-binding) vote to approve named executive officer compensation (“Say-on-Pay”);
4.To hold an advisory, non-binding vote on the frequency of holding votes on Say-on-Pay (once every year, every two years or three years);
5.To approve an increase in the number of shares available for issuance pursuant to the Ameri Holdings, Inc. 2015 Equity Incentive Award Plan;
6.To approve an amendment to the Amended and Restated Certificate of Incorporation of Ameri Holdings, Inc. to amend the certificate of designations for the Series A Preferred Stock of Ameri Holdings, Inc. to modify the dividend terms, eliminate voting rights of the Series A Preferred Stock with respect to the creation or issuance of parity or senior preferred stock and make certain related changes to such certificate of designations;
7.To approve the issuance of warrants to purchase 5,000,000 shares of common stock by the Company to the Series A Preferred Stock holders;
8.To transact such other business as may properly come before the annual meeting or any adjournment(s), postponement(s) or other delay(s) thereof.
|